News

News

Read our latest news below, or sign up for our annual newsletter to keep up to date.

AIMS-2-TRIALS is in the ‘Top 10’ IMI Projects

AIMS-2-TRIALS is in the ‘Top 10’ IMI Projects

A recent report published by the Innovative Medicines Initiative (IMI), the world’s largest public-private partnership in the life sciences, showed that AIMS-2-TRIALS have published the most papers out of all Phase 2 IMI-funded projects. Since the IMI was launched,...

read more
New project: European Autism Genomics Registry

New project: European Autism Genomics Registry

The genetics of autism are very complex. Some autistic people have a genetic syndrome associated with autism, like Angelman syndrome or dup15q syndrome, whilst others do not. Given the diversity of autism, it is important that research looks at the broad range of...

read more
AIMS-2-TRIALS consultation on data sharing

AIMS-2-TRIALS consultation on data sharing

Sharing scientific research data is important because it can help improve the quality, usefulness, and reliability of research. For example, it enables scientists to analyse larger data sets, which increases their ability to uncover patterns in the data. Data sharing...

read more
Recognising faces: microstates

Recognising faces: microstates

AIMS-2-TRIALS researchers have been exploring how people process faces, both in autistic and non-autistic individuals. Previous research has shown that most people find it trickier to recognise upside down (inverted) faces compared to upright faces (see image on the...

read more
AIMS-2-TRIALS Work Package Updates for 2022

AIMS-2-TRIALS Work Package Updates for 2022

Research studies across the lifespan Project updates:  Over the past year, recruitment of participants and families to our AIMS-2-TRIALS cohort studies has grown at its most significant rate since pandemic-related restrictions on face-to-face research eased. The Leads...

read more
The Value of Treatment

The Value of Treatment

Find out about the outcome of our research projects looking at care pathways for autism and autism with co-occurring epilepsy, including data from the UK, Spain and Italy. We explore treatment gaps/unmet needs, screening and diagnosis times, funding and make...

read more
AIMS-2-TRIALS Partners involved in Lancet Commission

AIMS-2-TRIALS Partners involved in Lancet Commission

The Lancet has launched a first-of-its-kind Commission that “aims to answer the question of what can be done in the next 5 years to address the current needs of autistic individuals and families worldwide.” The Commission’s 32 representatives are co-led by Prof Tony...

read more
Reviewing healthcare barriers for autistic people

Reviewing healthcare barriers for autistic people

Our news item published on May 19th 2021 highlighted ways that the COVID-19 pandemic has exacerbated existing healthcare inequalities for autistic people. We now report on a recently-published systematic review that aimed to identify the broader range of healthcare...

read more
COVID exacerbates healthcare inequalities for autistic people

COVID exacerbates healthcare inequalities for autistic people

According to a new AIMS-2-TRIALS study published today in BMJ OPEN, the COVID-19 pandemic has further exacerbated existing healthcare inequalities for autistic people and has likely contributed to disproportionate increases in morbidity and mortality, mental health/...

read more
Distinct behavioural profiles of autism matter

Distinct behavioural profiles of autism matter

New AIMS-2-TRIALS research finds that autistic people with more social communication difficulties have different brain connectivity compared to autistic people with an equal mix of social traits and repetitive behaviours. Background A diagnosis of autism includes the...

read more
Professor Emily Jones on PsychologiCall Podcast

Professor Emily Jones on PsychologiCall Podcast

Listen to AIMS-2-TRIALS researcher Professor Emily Jones talk about her work on theta waves and information processing on the PsychologiCall podcast. During this podcast she talks about her research looking at how changes in early brain activity may predict later...

read more
What do AIMS-2-TRIALS Autism Representatives (A-Reps) do?

What do AIMS-2-TRIALS Autism Representatives (A-Reps) do?

Autistic people have long made the case that they should be involved in research about them and many researchers now consider this to be part of the standard research process. This involvement is sometimes referred to as ‘participatory research’ and can be done in a...

read more
Are there differences in the brains of autistic men and women?

Are there differences in the brains of autistic men and women?

Around three times as many males are diagnosed with autism than females, which suggests that sex-related biological factors play a key role in its development. However, little is known about the ways that autistic males and females differ in terms of brain structure...

read more
AIMS-2-TRIALS research into autism subtypes at Birkbeck

AIMS-2-TRIALS research into autism subtypes at Birkbeck

Professor Emily Jones and her team at Birkbeck University of London are undertaking a range of research activities that follow children from infancy, or even pregnancy, into later childhood. Many of the children have parents or older siblings who are autistic and...

read more
New AIMS-2-TRIALS database developed by Institut Pasteur

New AIMS-2-TRIALS database developed by Institut Pasteur

A world-leading AIMS-2-TRIALS team at the Institut Pasteur (Paris) has developed a secure database to address the needs of the AIMS-2-TRIALS project, ensuring that large, multidisciplinary datasets from participants across Europe are secure, GDPR compliant and easily...

read more
UPDATE: Favourable feedback from European Medicines Agency

UPDATE: Favourable feedback from European Medicines Agency

Letters of support now available on the EMA website. The AIMS-2-TRIALS consortium has received feedback (qualification advice) from the European Medicines Agency (EMA) on the further exploration of EEG (electroencephalography) as a potential ‘biomarker’ in autism...

read more
Researcher training opportunities

Researcher training opportunities

The Early Career Researcher Autism Network (ECRAN) hosted their first workshop in July 2020. The workshop brought together 25 postdocs, 10 PhD students and 6 members of the autism community who are researchers themselves or who have a research interest in autism from...

read more
Autism: How gene alteration modifies social behavior

Autism: How gene alteration modifies social behavior

Prof. Peter Scheiffele’s team at the Biozentrum, University of Basel, has discovered a new connection between a genetic modification and social difficulties related to autism: A mutation in the neuroligin-3 gene reduces the effect of the “feel good hormone” oxytocin....

read more
Autism Representatives (A-Reps)

Autism Representatives (A-Reps)

The A-Reps are a group of autistic people, parents and carers from across Europe who have agreed to bring their perspectives on being autistic or caring for an autistic loved one to the AIMS-2-TRIALS research programme. They are coordinated by a team at the University...

read more
Understanding adaptive functioning in autism

Understanding adaptive functioning in autism

Adaptive functioning refers to the ability to manage the demands of day-to-day life. It can include areas such as self-care, travel, shopping, cooking, fine motor skills and communication. It is understood that autistic people may learn some of these skills at a...

read more
AIMS-2-TRIALS’ response to COVID-19

AIMS-2-TRIALS’ response to COVID-19

We are all very shocked and saddened by the effect that COVID-19 is having globally. We hope you are keeping safe and well during these uncertain and difficult times. We understand that some of you will be more affected than others either by being ill yourself, having...

read more
Autistic people’s social brain activity is not reduced

Autistic people’s social brain activity is not reduced

An article in Molecular Autism by AIMS-2-TRIALS researchers will report that - contrary to predictions made by previous research – in an analysis of one of the largest data sets of its kind, no group differences were found in the brain activity of autistic and...

read more
Researcher training opportunities

Researcher training opportunities

The Early Career Researcher Autism Network was launched earlier this year at the AIMS-2-TRIALS general assembly - an event that saw over thirty researchers share ideas about their training needs. To promote training opportunities for researchers in an early stage of...

read more

Want to get involved?

If you are interested in participating in a research study, you can sign up to our mailing list here (link to come). We will also publish details about studies that are recruiting via our participant recruitment page.

read more
Clinical trials begin at three AIMS-2-TRIALS sites

Clinical trials begin at three AIMS-2-TRIALS sites

Development of medicines is a key priority within the AIMS-2-TRIALS research programme and this will be achieved primarily via two clinical trials. A clinical trial is a specific type of research study that evaluates an intervention; in this case a medicine. The main...

read more
Prestigious scientific awards for consortium members

Prestigious scientific awards for consortium members

AIMS-2-TRIALS is celebrating prestigious awards received by two consortium members, both based at Kings College London. Oscar Marín, Director of the Centre for Developmental Neurobiology, was unanimously selected by an international jury to receive the Remedios Caro...

read more
A new publication for Autism-Europe

A new publication for Autism-Europe

Autism-Europe is an international autism association whose main objectives are to improve public awareness of autism and to advance the rights of autistic people and their families. In September, the third edition of their publication “People with Autism Spectrum...

read more
AIMS-2-TRIALS researchers at key events in Europe

AIMS-2-TRIALS researchers at key events in Europe

Autism Europe Congress Consortium members participated throughout the Autism Europe Congress 2019 on 13th - 15th September, delivering keynotes, moderating sessions and as part of the scientific committee. James Cusack (Autistica) chaired a keynote session on...

read more
Changing pupil size indicates social abilities in autism

Changing pupil size indicates social abilities in autism

The amount that autistic people’s pupils widen (dilate) when watching others interact and the speed at which this happens is linked with their understanding of social behaviour, shows a study led by AIMS-2-TRIALS researchers. The study is the first to record the...

read more
Declan Murphy & Gráinne McAlonan of KCL on BBC Radio 4

Declan Murphy & Gráinne McAlonan of KCL on BBC Radio 4

Declan Murphy and Gráinne McAlonan of Kings College London were recently featured on BBC Radio 4's 'D for Diagnosis' with Claudia Hammond, discussing the diagnosis of autism and co-occurring conditions. https://twitter.com/Aims2Trials/status/1158370309495578625

read more
Eye tracking holds clues to the emergence of autism

Eye tracking holds clues to the emergence of autism

Ten month old infants later diagnosed with autism use their gaze to attract other’s attention less often than those who are not autistic, shows research led by Terje Falck-Ytter at Uppsala University in Sweden, as part of AIMS-2-TRIALS. “Joint attention is extremely...

read more
Machine learning heralds a new era for autism research

Machine learning heralds a new era for autism research

Computer algorithms that can spot patterns in vast amounts of data will drive the future of autism research and help scientists to understand autism’s true complexity and diversity, say AIMS-2-TRIALS researchers in a recent review article. The algorithms’ power comes...

read more

An opportunity to influence European research

The Innovative Medicines Initiative (IMI) wants to hear from youApplications are open for a ‘pool of patient experts’, which will strengthen the role and voice of those with diseases and conditions addressed by IMI research. This will introduce the perspectives of...

read more

Autism Representatives chosen from nearly 100 applications

The recruitment of Autism Representatives for AIMS-2-TRIALS is now complete. In total, 96 applicants from 18 European countries (and one from the US) expressed interest in working with us. This included autistic people and family carers of autistic people. There were...

read more
Researchers reach out to the community

Researchers reach out to the community

AIMS-2-TRIALS researchers met with autistic people at events across Europe about the future of autism research. At Trinity College Dublin, Ireland, team members from the rare genetic conditions study led an event in February to foster two-way dialogue about the future...

read more